Table 2 Comparison of neoadjuvant hormonal therapy period treated with laparoscopic radical prostatectomy patients
From: Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
Variables | Group A* | Group B** |
|---|---|---|
No. of patients | 47 | 25 |
Mean age ± SD | 67.4 ± 5.6 | 68.3 ± 4.7 |
Preoperative serum PSA ± SD, ng/mL | 10.0 ± 3.9 | 9.38 ± 4.4 |
Biopsy Gleason grade, n(%) | ||
 ≤ 3 + 3 | 20 (42.6) | 10 (40.0) |
 3 + 4, 4 + 3 | 20 (42.6) | 5 (20.0) |
 ≥ 4 + 4 | 7 (14.9) | 10 (40.0) |
D’Amico risk classification, n(%) | ||
 low | 11 (23.4) | 3 (12.0) |
 intermediate | 17 (36.2) | 7 (28.0) |
 high | 19 (40.4) | 15 (60.0) |
Kind of neoadjuvant hormonal therapy | ||
 CAB | 32 (68.1) | 18 (72.0) |
 anti-androgen alone | 15 (31.9) | 7 (28.0) |
Pathological stage, n(%) | ||
 pT2 | 42 (89.4) | 20 (80.0) |
 pT3a | 3 (6.40) | 4 (16.0) |
 pT3b | 2 (4.30) | 1 (4.00) |
Median operative time, min | 286 (151–454) | 270 (152–410) |
Median blood loss, ml | 600 (90–3928) | 552 (95–1600) |
Positive surgical margin, n(%) | 13 (27.7) | 7 (28.0) |
Biochemical recurrence, n(%) | 13 (27.7) | *1 (4.00) |